Rebecca Ciszek, MOTR/L | |
192 Byron Rd, Gerrardstown, WV 25420-4594 | |
(708) 275-4752 | |
Not Available |
Full Name | Rebecca Ciszek |
---|---|
Gender | Female |
Speciality | Occupational Therapist |
Location | 192 Byron Rd, Gerrardstown, West Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1831564459 | NPI | - | NPPES |
1784 | Other | WV | LISCENCE OF OT |
011900659 | Other | VA | LICENSE OF OCCUPATIONAL THERAPY |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 1784 (West Virginia) | Secondary |
225X00000X | Occupational Therapist | 0119006509 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Rebecca Ciszek, MOTR/L 192 Byron Rd, Gerrardstown, WV 25420-4594 Ph: (708) 275-4752 | Rebecca Ciszek, MOTR/L 192 Byron Rd, Gerrardstown, WV 25420-4594 Ph: (708) 275-4752 |
News Archive
Community mental health clinics, where most specialty mental health treatment is delivered, have been relying more on independent contractors to treat patients, largely for budgetary reasons. Many of these clinics have simultaneously been moving towards the greater use of evidence-based psychosocial practices , broadly defined as talk therapies that are informed by rigorous research as well as clinician expertise and patient preferences.
Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQâ„¢ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
Therakos, Inc., a pioneer in the innovative treatment of extracorporeal photopheresis (ECP) for immune modulation therapy, today announced that the first patient has been enrolled in its Phase IIb clinical study evaluating the use of the company's photopheresis technology in the treatment of patients with moderate-to-severe chronic Graft-versus-Host Disease (GvHD).
Uninsured cancer patients are asked to pay anywhere from two to 43 times what Medicare would pay for chemotherapy drugs, according to a new study from the University of North Carolina at Chapel Hill.
"The Department of Veterans Affairs yesterday apologized repeatedly for a prostate-cancer program that gave incorrect radiation doses to veterans for six years at its main Philadelphia hospital," The Philadelphia Inquirer reports.
› Verified 6 days ago